🔗 Share this article

While the US continues making unprecedented adjustments to its vaccine guidelines, a particular individual has surfaced in a surprising turn: Dr. Tracy Beth Høeg, an American of Danish descent physician and epidemiologist who first made her name by expressing skepticism about coronavirus vaccines in the pandemic and has zeroed in on alleged fatalities following Covid immunization in her short time at the Food and Drug Administration.

Scheduled Changes to Childhood Immunization Schedule

Agency leaders had intended to unveil major revisions to the pediatric vaccine schedule earlier this month, aligning the US with the Danish national calendar, according to reports – a major change that would put the US out of alignment with a large portion of the world with little proof for public health gain. The announcement has been postponed until the coming year.

In place of the director of the vaccine center, Dr. Høeg is listed to present at the event. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to run the office this calendar year.

A Shift at the Agency

This interim role might represent a tighter collaboration between the drug and vaccine centers as Høeg and Dr. Prasad consolidate power at the regulatory agency – and it signals a greater focus upon dismantling long-standing vaccines at the FDA.

The new acting director has frequently advocated for discontinuing certain pediatric shot schedules in the US in order to be more like Denmark, a society with universal health coverage and a citizenry about the size of Wisconsin’s.

In her initial statements, she has continued to focus on vaccination policy – typically the responsibility of Prasad, head of the FDA’s CBER – instead of drug regulation.

Questions Over Qualifications

Høeg has no obvious background in drug development, oversight or leadership, which has been typical for past heads of the Center for Biologics Evaluation and Research. She has worked at the FDA as a senior adviser to the agency head and the vaccine center since March.

“She doesn’t seem to have the requisite experience” for running the pharmaceutical oversight division, remarked Jonathan Howard. “She has not conducted a randomized controlled trial. She has no expertise in managing a sizeable institution. She is not an expert in industry regulation.”

Past directors of CBER would “be deeply familiar with regulatory frameworks and the science of pharmaceutical innovation”, commented Janet Woodcock. “Clearly, she has not acquired the sort of resume that prior appointees who ran the center have had.”

This division has an vast range of responsibilities at the FDA, she pointed out.

“The public just pays attention on the novel medication approvals, but the generic program authorizes a multitude of off-brand pharmaceuticals. There’s a biologic copycat branch, OTC medication office and more, and all of those need to be looked after,” she noted. “The responsibility you neglect, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a significant leadership aspect to the role, which manages more than 5,000 staff members. “It is a huge administrative position, if you do it right,” the former official said.

Agency Reaction and Controversial Policies

In response to inquiries about Høeg’s credentials and whether this selection signifies greater collaboration among regulatory chiefs on immunizations, a press secretary stated that the “inquiries stem from inaccurate assumptions”.

“Her resume is consistent with the responsibilities of her role,” the official said, noting the time Dr. Høeg spent advising the agency head on “medication safety and approval science, including predictive safety algorithms and shot safety tracking”.

As acting director, Høeg assumes responsibility for the commissioner’s controversial expedited review system, a controversial rapid medication authorization process that apparently troubled her former heads. “By what process are these therapies being selected for this fast-track system? Who takes the decisions?” Howard questioned. “There is a lot of secrecy occurring at the agency right now.”

In general, he remarked, “the FDA seems to be moving towards laxer oversight of all drugs, with the exception of immunizations.”

Established History on Immunizations

Regarding vaccines, Høeg has a more documented, if concerning, history, Howard have noted. She released a analysis using non-validated crowd-sourced reports to assess the frequency of myocarditis after COVID-19 vaccination. She counseled the state of Florida chief medical officer Joseph Ladapo, who reportedly have altered data to imply Covid vaccinations are riskier than they are.

Among her “wish list” for the incoming administration included revising rules for recently developed shots and halting “non-essential” vaccines, she said following the vote on a podcast. At the agency, Høeg has allegedly floated the idea of barring teenage boys from obtaining COVID-19 vaccines.

“She’s an all-around ideologue who begins with her preconceived notions and reverse-engineers to accommodate the science in a very misleading, untruthful way,” Dr. Howard argued.

Consolidating Power and a “Revenge Tour”

Dr. Høeg became part of other contrarians, {like|